Viking Therapeutics Statistics
Total Valuation
VKTX has a market cap or net worth of $3.75 billion. The enterprise value is $3.05 billion.
Important Dates
The next confirmed earnings date is Wednesday, April 29, 2026, after market close.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VKTX has 115.89 million shares outstanding. The number of shares has increased by 3.33% in one year.
| Current Share Class | 115.89M |
| Shares Outstanding | 115.89M |
| Shares Change (YoY) | +3.33% |
| Shares Change (QoQ) | +1.50% |
| Owned by Insiders (%) | 2.40% |
| Owned by Institutions (%) | 62.74% |
| Float | 113.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.82 |
| P/TBV Ratio | 5.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.33, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.33 |
| Quick Ratio | 9.21 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7,023.96 |
Financial Efficiency
Return on equity (ROE) is -47.34% and return on invested capital (ROIC) is -32.33%.
| Return on Equity (ROE) | -47.34% |
| Return on Assets (ROA) | -30.27% |
| Return on Invested Capital (ROIC) | -32.33% |
| Return on Capital Employed (ROCE) | -61.55% |
| Weighted Average Cost of Capital (WACC) | 8.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$6.79M |
| Employee Count | 53 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.61% in the last 52 weeks. The beta is 0.82, so VKTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +29.61% |
| 50-Day Moving Average | 33.52 |
| 200-Day Moving Average | 32.77 |
| Relative Strength Index (RSI) | 42.92 |
| Average Volume (20 Days) | 2,114,356 |
Short Selling Information
The latest short interest is 23.11 million, so 19.94% of the outstanding shares have been sold short.
| Short Interest | 23.11M |
| Short Previous Month | 24.01M |
| Short % of Shares Out | 19.94% |
| Short % of Float | 20.44% |
| Short Ratio (days to cover) | 10.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -393.34M |
| Pretax Income | -359.64M |
| Net Income | -359.64M |
| EBITDA | n/a |
| EBIT | -393.34M |
| Earnings Per Share (EPS) | -$3.19 |
Full Income Statement Balance Sheet
The company has $705.74 million in cash and $137,000 in debt, giving a net cash position of $705.60 million or $6.09 per share.
| Cash & Cash Equivalents | 705.74M |
| Total Debt | 137,000 |
| Net Cash | 705.60M |
| Net Cash Per Share | $6.09 |
| Equity (Book Value) | 639.06M |
| Book Value Per Share | 5.57 |
| Working Capital | 638.93M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -278.69M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 431,000 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |